CA2348067A1 - Composition for extending post meal satiety - Google Patents
Composition for extending post meal satiety Download PDFInfo
- Publication number
- CA2348067A1 CA2348067A1 CA002348067A CA2348067A CA2348067A1 CA 2348067 A1 CA2348067 A1 CA 2348067A1 CA 002348067 A CA002348067 A CA 002348067A CA 2348067 A CA2348067 A CA 2348067A CA 2348067 A1 CA2348067 A1 CA 2348067A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- weight
- nutritional composition
- meal
- satiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/56—Protease inhibitors from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pediatric Medicine (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Polymers & Plastics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A nutritional composition in a dry powder form including an extract of potatoes that provides a source of proteinase inhibitor that is mixed with water and ingested before a meal which extends satiety and thereby reduces appetite. The nutritional composition includes between about 10 % and about 80 % by weight of a protein, between about 10 % and about 40 % by weight of a medium to long chain fatty acid, between about 2 % and about 5 % by weight o f a calcium salt, and between about 1 % and about 5 % by weight of a proteinas e inhibitor provided by the extract of potatoes.
Description
COMPOSITION FOR EXTENDING POST MEAL SATIETY
BACKGROUND OF THE INVENTION
Field of Invention The present invention relates to a nutritional composition for extending satiety following a meal. More particularly the nutritional composition includes protein, medium and/or long chain fatty acids and calcium to stimulate the secretion of cholecystokinin a gastric peptide, and a source ofproteinase inhibitor extracted from potatoes that prevents the breakdown of cholecystokinin. By increasing and sustaining the levels of cholecystokinin, the present invention extends satiety.
Back.~round of the Prior Art Over the last forty years there has been extensive research conducted on mechanisms that would extend satiety following the ingestion of a meal. The benefits of such an invention have obvious utility in producing weight loss. Weight loss research has focused on three areas.
1 ~ Because the brain plays an essential role in the control of appetite, researchers have looked at various neurotransmitters, specifically, serotonin, dopamine and nor-epinephrine. A number of prescription and over-the-counter products have been developed which influence these neurotransmitters, thereby reducing appetite. Reducing appetite pharmacologically has a number of drawbacks, including a loss of effectiveness over a period of time. Drugs that affect neurotransmitters also affect the central nervous systems and can cause jitteriness and anxiety. In addition, these agents can produce cardiovascular effects that may even be fatal.
A second approach has focused on slowing gastric emptying thereby creating a feeling of fullness. This approach utilizes insoluble fibers, which slow the movement of food through the gastrointestinal tract. The disadvantage with the use of fiber is that the quantities needed to 2s produce an effect create an unpalatable diet as well as numerous gastrointestinal effects including bloating, gas and diarrhea.
A third approach investigates stimulating the body's satiety mechanism. When food is consumed a peptide is released called Cholecystokinin Releasing Protein (CCK-RP).
Cholecystokinin Releasing Protein then stimulates the release of cholecystokinin in the gut.
Cholecystokinin has been shown to increase satiety. When cholecystokinin is released it also stimulates the release of enzymes which inactivate CCK-RP. When CCK-RP is inactivated, CCK levels drop and the feeling of satiation is diminished. Studies have shown that cholecystokinin is extremely effective in extending satiety following ingestion of a meal.
Although CCK has been shown to extend satiety and reduce food intake, a major disadvantage is that it must be given intravenously. When administered orally, CCK is inactivated by gastric enzymes. This has severely limited its use as a potential weight loss agent.
A number of nutritive agents can stimulate the release of cholecystokinin.
Researchers have shown that protein, fat (particularly medium chain fatty acids), and calcium stimulate the release of CCK.
United States Patent No. 4,491,78 discloses the oral administration of a trypsin inhibitor 1 ~ to stimulate satiety by stimulating the release of cholecystokinin. The trypsin inhibitor was postulated to act by inhibiting the negative feedback signal for cholecystokinin secretion. In this fashion, the trypsin inhibitor sustained levels of cholecystokinin thereby extending satiety.
A number of studies have shown that proteinase inhibitor extracted from potatoes stimulates the release of cholecystokinin.
There is a definite need in the art for a nutritional intervention composition that can be taken orally, stimulate cholecystokinin levels prior to the initiation of a meal and sustain cholecystokinin levels and satiety for an extended period following consumption of a meal. An important element of this invention is the design of a product taken in a specified interval prior to the commencement of a meal. Thus, satiety levels are already enhanced before the meal, 2~ decreasing the quantity of food consumed during that meal.
SUMMARY OF THE INVENTION
The present invention provides for nutritional composition in a dry powder form for extending satiety following ingestion of a meal.
The dry nutritional composition includes proteins in the range of 10% to 80%.
The protein can be in the form of soy, whey, casein or a specific amino acid mixture containing essential amino acids or of the amino acid phenylalanine.
The dry nutritional composition also includes the mineral calcium in the range of 2% to 6%. The calcium can be in the form of a salt including calcium chloride, calcium carbonate, calcium lactate etc.
The dry nutritional composition also includes medium and/or long chain fatty acids (Cz2-C») in the range of 10°~0-40%.
The dry nutritional composition also includes a source of proteinase inhibitor extracted from potatoes wherein the protease inhibitor is present in the range of 0.02%-5%.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is a graphical representation of the responses of test subjects as to their feeling of satiety taken in fifteen minute intervals over a three and one-half hour period following a meal, showing both subjects who were administered a placebo and subjects who were administered a nutritional supplement according to the present invention.
Fig. 2 is a graphical representation of the responses of test subjects as to their feeling of hunger taken in fifteen minute intervals over a three and one-half hour period following a meal, showing both subjects who were administered a placebo and subjects who were administered a nutritional supplement according to the present invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The nutritional composition for nutritional intervention for extending satiety includes nutritional agents being protein, medium and/or chain fatty acids, calcium, an extract ofpotatoes 2~ containing proteinase inhibitor, and, in a preferred form, flavoring agents and coloring agents.
The proteinase inhibitor is a heat stable protein present in potatoes and in extracts from potatoes and has a molecular weight of approximately 21,000. It is both a trypsin and chymotrypsin inhibitor, with its critical functionality being that it stimulates the release of cholecystokinin.
The protease inhibitor with the desired activity is present in potatoes and in more concentrated form in commercially available extracts or fractions of potatoes, such as coarse potato flour and potato fiber. Specifically, coarse potato flour available from Nonpariel Company contains approximately 0.49 mg of potato protease inhibitor two per gram, and Paselli PPC potato flour available from Avebe Company, The Netherlands, contains about 1.35 mg potato protease inhibitor rivo per gram. A method of extraction of a relatively pure proteinase inhibitor with the desired activity of the present invention is described in Bryant, J., Green, T. R., Gurusaddalah, T., and Ryan, C. A. {1976), Biochem. I5, 3418.
Experiment 1 This study was conducted with 21 subjects having a mean BMI =31.2 kglm2 (range 27.0 - 35.8) and mean age = 30.9 years (range 22 - 45). The study was a cross over design consisting of two parts. In the first phase the subjects were either given a placebo whose isocaloric I ~ composition was equal to the nutritional drink composition or the nutritional drink composition.
Both treatments were administered in 8 oz. of water 15 minutes prior to the meal. The meal consisted of 460 calories. Subjects were required to consume the meal within 15 minutes.
Following the consumption of the meal subjects were asked to rate their feelings of hunger and satiety on 6 visual analog scales every 15 minutes for 3 '/2 hours.
The nutritional drink composition is set out below:
wo ovmsa~ Pcr~usoonois~
Nutritional Drink Composition Constituent Grams %
Whey Protein 13.00 71.5 Non-Dairy Creamer4.00 22.0 containing 50% oleic acid Calcium Lactate0.635 3.5 Flavor 0.19 1.0 Color 0.05 0.3 POT 2' 0.30 1.7 ~ POT ? includes10% by weight einase approx. of the prot inhibitor Hunger ratings following ingestion of the nutritional drink composition were significantly decreased throughout the post-meal measurement period, reaching a 30% decrease by 3 hours post meal (p=0.033). Consistent with this finding, fullness ratings were significantly greater starting 3 hours post meal (37% increase, p=0.043). No differences in subjective ratings of other hunger-related items, or in thirst, were observed between the conditions.
Accordingly, an advantage of the present invention is that it provides for a nutritional intervention composition for extending satiety and reducing hunger following the termination of a meal.
Experiment 2:
This study was conducted with 21 subjects having a mean BMI =31.2 kg/mZ (range 27.0 I ~ - 35.8) and mean age = 30.9 years (range 22 - 45). During the diet, subjects drank 8 oz. (80 kcal) of the nutritional drink composition of Experiment 1 twice daily fifteen minutes before lunch and dinner. The effect of the nutritional drink composition on satiety was measured in a laboratory before and in the fourth week of the diet. On separate days subjects ingested the nutritional drink composition beverage or a placebo beverage (matched for volume and energy) fifteen minutes before a 350 calorie meal. Subjects rated hunger and fullness on visual analog scales every 1 S minutes for 3 '/2 hours.
The results of the study show that after four weeks on the diet, fullness ratings after lunch were higher after the consumption of the nutritional drink composition than the placebo beverage (mean ~ SD for alI time intervals = 71.0 t 17.3 vs. 65.5 ~ 16.7, p < 0.05).
Hunger ratings were 32% lower after the protease inhibitor than the placebo beverage (10.5 t 12.0 vs. 15.4 t 13.3, p < 0.01 ). There were no adverse reactions to the nutritional drink composition, and subjects reported that it helped them to reduce their food intake. Weight loss was significant (2.0 t 1.1 kg in 4 weeks, p < 0.001 ).
Accordingly an advantage of the present invention is that it provides continual effectiveness over a 30-day period and by extending satiety results in significant weight loss.
I 0 The source of the protease inhibitor may vary depending on the particular application for the satiety extending product of the present invention. For example, while coarse potato flour contains a significant amount of the protease inhibitor, it is difficult to disperse in water. Those having ordinary skill in the art, following the teachings of the invention set out above can readily accomplish determining an appropriate source of protease inhibitor as well as other components 15 that may be added to the composition to improve characteristics such as mouth feel, taste, and the like. Although the description above contains many specificities, these should not be construed as limiting the scope of the invention, but as merely providing illustrations of some of the presently preferred embodiments of this invention.
BACKGROUND OF THE INVENTION
Field of Invention The present invention relates to a nutritional composition for extending satiety following a meal. More particularly the nutritional composition includes protein, medium and/or long chain fatty acids and calcium to stimulate the secretion of cholecystokinin a gastric peptide, and a source ofproteinase inhibitor extracted from potatoes that prevents the breakdown of cholecystokinin. By increasing and sustaining the levels of cholecystokinin, the present invention extends satiety.
Back.~round of the Prior Art Over the last forty years there has been extensive research conducted on mechanisms that would extend satiety following the ingestion of a meal. The benefits of such an invention have obvious utility in producing weight loss. Weight loss research has focused on three areas.
1 ~ Because the brain plays an essential role in the control of appetite, researchers have looked at various neurotransmitters, specifically, serotonin, dopamine and nor-epinephrine. A number of prescription and over-the-counter products have been developed which influence these neurotransmitters, thereby reducing appetite. Reducing appetite pharmacologically has a number of drawbacks, including a loss of effectiveness over a period of time. Drugs that affect neurotransmitters also affect the central nervous systems and can cause jitteriness and anxiety. In addition, these agents can produce cardiovascular effects that may even be fatal.
A second approach has focused on slowing gastric emptying thereby creating a feeling of fullness. This approach utilizes insoluble fibers, which slow the movement of food through the gastrointestinal tract. The disadvantage with the use of fiber is that the quantities needed to 2s produce an effect create an unpalatable diet as well as numerous gastrointestinal effects including bloating, gas and diarrhea.
A third approach investigates stimulating the body's satiety mechanism. When food is consumed a peptide is released called Cholecystokinin Releasing Protein (CCK-RP).
Cholecystokinin Releasing Protein then stimulates the release of cholecystokinin in the gut.
Cholecystokinin has been shown to increase satiety. When cholecystokinin is released it also stimulates the release of enzymes which inactivate CCK-RP. When CCK-RP is inactivated, CCK levels drop and the feeling of satiation is diminished. Studies have shown that cholecystokinin is extremely effective in extending satiety following ingestion of a meal.
Although CCK has been shown to extend satiety and reduce food intake, a major disadvantage is that it must be given intravenously. When administered orally, CCK is inactivated by gastric enzymes. This has severely limited its use as a potential weight loss agent.
A number of nutritive agents can stimulate the release of cholecystokinin.
Researchers have shown that protein, fat (particularly medium chain fatty acids), and calcium stimulate the release of CCK.
United States Patent No. 4,491,78 discloses the oral administration of a trypsin inhibitor 1 ~ to stimulate satiety by stimulating the release of cholecystokinin. The trypsin inhibitor was postulated to act by inhibiting the negative feedback signal for cholecystokinin secretion. In this fashion, the trypsin inhibitor sustained levels of cholecystokinin thereby extending satiety.
A number of studies have shown that proteinase inhibitor extracted from potatoes stimulates the release of cholecystokinin.
There is a definite need in the art for a nutritional intervention composition that can be taken orally, stimulate cholecystokinin levels prior to the initiation of a meal and sustain cholecystokinin levels and satiety for an extended period following consumption of a meal. An important element of this invention is the design of a product taken in a specified interval prior to the commencement of a meal. Thus, satiety levels are already enhanced before the meal, 2~ decreasing the quantity of food consumed during that meal.
SUMMARY OF THE INVENTION
The present invention provides for nutritional composition in a dry powder form for extending satiety following ingestion of a meal.
The dry nutritional composition includes proteins in the range of 10% to 80%.
The protein can be in the form of soy, whey, casein or a specific amino acid mixture containing essential amino acids or of the amino acid phenylalanine.
The dry nutritional composition also includes the mineral calcium in the range of 2% to 6%. The calcium can be in the form of a salt including calcium chloride, calcium carbonate, calcium lactate etc.
The dry nutritional composition also includes medium and/or long chain fatty acids (Cz2-C») in the range of 10°~0-40%.
The dry nutritional composition also includes a source of proteinase inhibitor extracted from potatoes wherein the protease inhibitor is present in the range of 0.02%-5%.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is a graphical representation of the responses of test subjects as to their feeling of satiety taken in fifteen minute intervals over a three and one-half hour period following a meal, showing both subjects who were administered a placebo and subjects who were administered a nutritional supplement according to the present invention.
Fig. 2 is a graphical representation of the responses of test subjects as to their feeling of hunger taken in fifteen minute intervals over a three and one-half hour period following a meal, showing both subjects who were administered a placebo and subjects who were administered a nutritional supplement according to the present invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The nutritional composition for nutritional intervention for extending satiety includes nutritional agents being protein, medium and/or chain fatty acids, calcium, an extract ofpotatoes 2~ containing proteinase inhibitor, and, in a preferred form, flavoring agents and coloring agents.
The proteinase inhibitor is a heat stable protein present in potatoes and in extracts from potatoes and has a molecular weight of approximately 21,000. It is both a trypsin and chymotrypsin inhibitor, with its critical functionality being that it stimulates the release of cholecystokinin.
The protease inhibitor with the desired activity is present in potatoes and in more concentrated form in commercially available extracts or fractions of potatoes, such as coarse potato flour and potato fiber. Specifically, coarse potato flour available from Nonpariel Company contains approximately 0.49 mg of potato protease inhibitor two per gram, and Paselli PPC potato flour available from Avebe Company, The Netherlands, contains about 1.35 mg potato protease inhibitor rivo per gram. A method of extraction of a relatively pure proteinase inhibitor with the desired activity of the present invention is described in Bryant, J., Green, T. R., Gurusaddalah, T., and Ryan, C. A. {1976), Biochem. I5, 3418.
Experiment 1 This study was conducted with 21 subjects having a mean BMI =31.2 kglm2 (range 27.0 - 35.8) and mean age = 30.9 years (range 22 - 45). The study was a cross over design consisting of two parts. In the first phase the subjects were either given a placebo whose isocaloric I ~ composition was equal to the nutritional drink composition or the nutritional drink composition.
Both treatments were administered in 8 oz. of water 15 minutes prior to the meal. The meal consisted of 460 calories. Subjects were required to consume the meal within 15 minutes.
Following the consumption of the meal subjects were asked to rate their feelings of hunger and satiety on 6 visual analog scales every 15 minutes for 3 '/2 hours.
The nutritional drink composition is set out below:
wo ovmsa~ Pcr~usoonois~
Nutritional Drink Composition Constituent Grams %
Whey Protein 13.00 71.5 Non-Dairy Creamer4.00 22.0 containing 50% oleic acid Calcium Lactate0.635 3.5 Flavor 0.19 1.0 Color 0.05 0.3 POT 2' 0.30 1.7 ~ POT ? includes10% by weight einase approx. of the prot inhibitor Hunger ratings following ingestion of the nutritional drink composition were significantly decreased throughout the post-meal measurement period, reaching a 30% decrease by 3 hours post meal (p=0.033). Consistent with this finding, fullness ratings were significantly greater starting 3 hours post meal (37% increase, p=0.043). No differences in subjective ratings of other hunger-related items, or in thirst, were observed between the conditions.
Accordingly, an advantage of the present invention is that it provides for a nutritional intervention composition for extending satiety and reducing hunger following the termination of a meal.
Experiment 2:
This study was conducted with 21 subjects having a mean BMI =31.2 kg/mZ (range 27.0 I ~ - 35.8) and mean age = 30.9 years (range 22 - 45). During the diet, subjects drank 8 oz. (80 kcal) of the nutritional drink composition of Experiment 1 twice daily fifteen minutes before lunch and dinner. The effect of the nutritional drink composition on satiety was measured in a laboratory before and in the fourth week of the diet. On separate days subjects ingested the nutritional drink composition beverage or a placebo beverage (matched for volume and energy) fifteen minutes before a 350 calorie meal. Subjects rated hunger and fullness on visual analog scales every 1 S minutes for 3 '/2 hours.
The results of the study show that after four weeks on the diet, fullness ratings after lunch were higher after the consumption of the nutritional drink composition than the placebo beverage (mean ~ SD for alI time intervals = 71.0 t 17.3 vs. 65.5 ~ 16.7, p < 0.05).
Hunger ratings were 32% lower after the protease inhibitor than the placebo beverage (10.5 t 12.0 vs. 15.4 t 13.3, p < 0.01 ). There were no adverse reactions to the nutritional drink composition, and subjects reported that it helped them to reduce their food intake. Weight loss was significant (2.0 t 1.1 kg in 4 weeks, p < 0.001 ).
Accordingly an advantage of the present invention is that it provides continual effectiveness over a 30-day period and by extending satiety results in significant weight loss.
I 0 The source of the protease inhibitor may vary depending on the particular application for the satiety extending product of the present invention. For example, while coarse potato flour contains a significant amount of the protease inhibitor, it is difficult to disperse in water. Those having ordinary skill in the art, following the teachings of the invention set out above can readily accomplish determining an appropriate source of protease inhibitor as well as other components 15 that may be added to the composition to improve characteristics such as mouth feel, taste, and the like. Although the description above contains many specificities, these should not be construed as limiting the scope of the invention, but as merely providing illustrations of some of the presently preferred embodiments of this invention.
Claims (5)
1. A nutritional composition in a dry powder form that is mixed with water and ingested before a meal which extends satiety and thereby reduces appetite, comprising:
(a) a protein comprising between about 10% and about 80% by weight of said dry composition;
(b) one or more fatty acids comprising between about 10% and about 40% by weight of said dry composition;
(c) a calcium salt comprising between about 2% and about 5% by weight of said dry composition; and (d) an extract of potatoes providing a source of proteinase inhibitor that comprises between about 0.02% and about 5% by weight of said dry composition.
(a) a protein comprising between about 10% and about 80% by weight of said dry composition;
(b) one or more fatty acids comprising between about 10% and about 40% by weight of said dry composition;
(c) a calcium salt comprising between about 2% and about 5% by weight of said dry composition; and (d) an extract of potatoes providing a source of proteinase inhibitor that comprises between about 0.02% and about 5% by weight of said dry composition.
2. A nutritional composition as defined in claim 1, wherein said fatty acid comprises oleic acid.
3. A nutritional composition as defined in claim 1, further comprising a water soluble flavoring selected from the group including natural extracts and artificially produced extract components of apple, banana, cherry, cinnamon, cranberry, grape, honeydew, honey, kiwi, lemon, lime, orange, peach, peppermint, pineapple, raspberry, tangerine, watermelon, and wild cherry.
4. A nutritional composition as defined in claim 1, further comprising a colorant selected from the group including water soluble natural or artificial dyes of blue, green, orange, red, violet, and yellow.
5. A nutritional composition as defined in claim 1, further comprising a colorant selected from the group including iron oxide dyes, ultramarine pigments of blue, pink, red, and violet.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14589299P | 1999-07-27 | 1999-07-27 | |
US60/145,892 | 1999-07-27 | ||
PCT/US2000/020157 WO2001017541A1 (en) | 1999-07-27 | 2000-07-25 | Composition for extending post meal satiety |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2348067A1 true CA2348067A1 (en) | 2001-03-15 |
Family
ID=22515008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002348067A Abandoned CA2348067A1 (en) | 1999-07-27 | 2000-07-25 | Composition for extending post meal satiety |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1115409A4 (en) |
JP (2) | JP2003508490A (en) |
KR (1) | KR20010075394A (en) |
AU (1) | AU779377C (en) |
BR (1) | BR0006959A (en) |
CA (1) | CA2348067A1 (en) |
MX (1) | MXPA01003054A (en) |
WO (1) | WO2001017541A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6686456B2 (en) | 2001-07-06 | 2004-02-03 | Kemin Foods, L.C. | Method for the elimination of Kunitz and Bowman-Birk trypsin inhibitors and carboxypeptidase inhibitor from potato proteins |
JP2005015358A (en) * | 2003-06-25 | 2005-01-20 | Pharma Design Inc | Medicinal composition used for treating eating disorder |
WO2006110731A2 (en) * | 2005-04-11 | 2006-10-19 | University Of Tennessee Research Foundation | Stable dairy components effective for fat loss |
JP2010094085A (en) * | 2008-10-17 | 2010-04-30 | Pola Chem Ind Inc | Food composition for dieting use |
JP5691105B2 (en) * | 2009-01-30 | 2015-04-01 | 株式会社東洋新薬 | Taste improvement method of food containing potato extract |
EP2227966B1 (en) * | 2009-02-25 | 2016-07-27 | Coöperatie Avebe U.A. | Condiment |
JP5672588B2 (en) * | 2009-05-26 | 2015-02-18 | 株式会社東洋新薬 | Diet composition |
WO2011068150A1 (en) * | 2009-12-04 | 2011-06-09 | 株式会社東洋新薬 | Glucagon-like peptide-1 secretion enhancer |
CN107334875A (en) * | 2017-08-30 | 2017-11-10 | 南宁学院 | A kind of medicinal liquor for treating diarrhoea and preparation method thereof |
CN111493254A (en) * | 2020-04-10 | 2020-08-07 | 苏州绿叶日用品有限公司 | A solid beverage containing rhizoma Solani Tuber osi extract and its preparation method |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4491578A (en) * | 1982-06-14 | 1985-01-01 | Peikin Steven R | Method of stimulating satiety in mammals |
US4833128A (en) * | 1984-12-28 | 1989-05-23 | Neil Solomon | Dietary supplement |
JPH0699321B2 (en) * | 1990-01-22 | 1994-12-07 | 不二製油株式会社 | Appetite suppressant and food containing the same |
US5468727A (en) * | 1990-12-13 | 1995-11-21 | Board Of Regents, The University Of Texas System | Methods of normalizing metabolic parameters in diabetics |
US5221668A (en) * | 1992-02-26 | 1993-06-22 | Abbott Laboratories | Nutritional product for trauma and surgery patients |
NZ260933A (en) * | 1993-07-16 | 1996-07-26 | Hercules Inc | Cation-complexed polysaccharides; use in foods and pharmaceuticals |
US5340603A (en) * | 1993-08-30 | 1994-08-23 | Abbott Laboratories | Nutritional product for human infants having chronic lung disease |
KR100406912B1 (en) * | 1994-08-05 | 2004-02-18 | 위스콘신 얼럼나이 리서어치 화운데이션 | CCK Antibodies Used to Improve Feed Efficiency |
US5595772A (en) * | 1995-06-07 | 1997-01-21 | Massachusetts Institute Of Technology | Composition and methods for losing weight |
ATE362715T1 (en) * | 1997-06-23 | 2007-06-15 | Nestle Sa | COMPOSITION FOR THE NUTRITION OF DIABETIC PEOPLE |
US6475539B1 (en) * | 1998-05-07 | 2002-11-05 | Abbott Laboratories | Nutritionally complete low pH enteral formula |
US6051236A (en) * | 1998-11-12 | 2000-04-18 | Pacifichealth Laboratories, Inc. | Composition for optimizing muscle performance during exercise |
US6025363A (en) * | 1998-11-17 | 2000-02-15 | Giles, Jr.; James A. | Composition for suppressing appetite |
-
2000
- 2000-07-25 AU AU63704/00A patent/AU779377C/en not_active Ceased
- 2000-07-25 JP JP2001521331A patent/JP2003508490A/en active Pending
- 2000-07-25 CA CA002348067A patent/CA2348067A1/en not_active Abandoned
- 2000-07-25 MX MXPA01003054A patent/MXPA01003054A/en active IP Right Grant
- 2000-07-25 KR KR1020017003896A patent/KR20010075394A/en not_active Application Discontinuation
- 2000-07-25 EP EP00950624A patent/EP1115409A4/en not_active Withdrawn
- 2000-07-25 WO PCT/US2000/020157 patent/WO2001017541A1/en not_active Application Discontinuation
- 2000-07-25 BR BR0006959-0A patent/BR0006959A/en not_active IP Right Cessation
-
2005
- 2005-08-15 JP JP2005235268A patent/JP2005336208A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2005336208A (en) | 2005-12-08 |
JP2003508490A (en) | 2003-03-04 |
MXPA01003054A (en) | 2003-07-14 |
AU6370400A (en) | 2001-04-10 |
EP1115409A4 (en) | 2005-04-13 |
WO2001017541A1 (en) | 2001-03-15 |
AU779377B2 (en) | 2005-01-20 |
EP1115409A1 (en) | 2001-07-18 |
KR20010075394A (en) | 2001-08-09 |
BR0006959A (en) | 2001-06-26 |
AU779377C (en) | 2005-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6838431B2 (en) | Nutritional intervention composition containing a source of proteinase inhibitor extending post meal satiety | |
CN101061860B (en) | Leucine-rich nutritional compositions | |
US6468962B1 (en) | Nutritional intervention composition for enhancing and extending satiety | |
Balch | Prescription for nutritional healing | |
US7300665B2 (en) | Nocturnal muscle enhancing composition and method | |
CN101212961A (en) | HMB compositions and uses thereof | |
US8388949B2 (en) | Compositions comprising pantothenic acid and their use for stimulating appetite | |
JP2010195779A (en) | Hydrolysate of crocin | |
US20060171992A1 (en) | Blood glucose regulating composition | |
TW200812503A (en) | Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass | |
JPH05252905A (en) | Food/beverage | |
AU779377B2 (en) | Composition for extending post meal satiety | |
US6265391B1 (en) | Method for preventing peripheral nerve damage | |
KR20150101458A (en) | Synergistic dietary supplement for enhancing physical performance | |
US8722614B2 (en) | Adiponectin production enhancer | |
EP1358878A1 (en) | Remedies/preventives for inflammatory diseases | |
US20040077530A1 (en) | Composition for reducing caloric intake | |
US20060135444A1 (en) | Combination of flavonoid and procyanidin for the reduction of the mammalian appetite | |
AU685153B2 (en) | Reduced absorption of fatty acids | |
KR0148462B1 (en) | Preparation process of brainactivating soft capsule | |
Ohki et al. | The Japanese nutritional health beverage market | |
Lagua | T. Abbreviation for temperature. T3• Abbreviation for triiodothyronine, a thyroid hormone. See Thyroid gland. T 4'Abbreviation for tetraiodothyronine | |
Furber | Nutrition, Diet, and Supplements for Peak Physical & Mental Performance | |
KR20070001631A (en) | Obesity Inhibitory Composition Containing Prickly Pear Extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |